01—Abstract
Summary
Summary of the 10-K filed August 17, 1995. Cited figures are marked; the original filing is the authoritative source.
Archer-Daniels-Midland's fiscal 1995 10-K (year ended June 30, 1995) shows a company at record scale and profitability.
Net sales and other operating income rose 11% to a record $12.7 billiona, driven mainly by a 9% increase in volumes and a 2% rise in average selling prices. Net earnings jumped 64% to $796 million ($1.47 per share), up from $484 million ($0.89 per share) in fiscal 1994. The gain was helped by a $43 million pre-tax gain on the sale of the British Arkady bakery ingredient business, and the earnings reflect strong export demand for vegetable oils and favorable oilseed processing margins.
Oilseed products remain the core, contributing 60% of sales. Balance sheet liquidity is strong, with $1.1 billionb in cash and marketable securities, working capital of $2.5 billion, shareholders' equity of $5.9 billion, and a long-term debt-to-capital ratio near 24%. Credit ratings remain high (S&P commercial paper top rating, long-term debt AA-; Moody's Aa2).
The primary risk for investors is legal rather than operational. The company disclosed a federal grand jury antitrust investigation in the food additives industry, focused on possible price-fixing of lysine, citric acid, and high fructose corn syrup. Following the June 1995 announcement, roughly 15 putative securities and antitrust class actions and at least 12 shareholder derivative suits were filed.
Management says the outcome cannot yet be determined and has recorded no provision for liability, so potential damages, fines, and sanctions remain an open contingency. Other items include a Illinois EPA permitting proceeding and about 24 Superfund PRP matters, both described by management as not material. On the growth side, ADM spent roughly $3.4 billionc over the last five years on plants, expansions, and acquisitions, and it is expanding its bioproducts line (amino acids, vitamins, and specialty ingredients).
The company also reshaped its portfolio, contributing rice milling and some feed operations to joint ventures and disposing of its sugar subsidiary in July 1995. Results were supported by a 5% stock dividend and a three-for-two stock split, while the company repurchased $180 milliond of stock during the year.
02—Key points
Key Highlights
- Record net sales and other operating income of $12.7 billion, up 11% from $11.4 billion, on 9% volume growth and a 2% rise in average selling prices
- Net earnings rose 64% to $796 million ($1.47 per share) from $484 million ($0.89 per share), including a $43 million pre-tax gain on the sale of the British Arkady bakery ingredient business
- Oilseed products generated 60% of sales ($7.6 billion, up 15%), with strong export demand for vegetable oils and good domestic meal demand
- Strong liquidity: $1.1 billion in cash and marketable securities, $2.5 billion working capital, and a current ratio of 3.2; long-term debt was about 24% of total capital
- Shareholders' equity grew to $5.9 billion ($10.99 per share) and the company bought back $180 million of stock during the year
- Material legal exposure: a federal grand jury antitrust probe into lysine, citric acid, and high fructose corn syrup, plus roughly 15 securities/antitrust class actions and at least 12 shareholder derivative suits; no liability has been accrued
- Continued expansion of bioproducts (amino acids, vitamins, specialty ingredients) and $3.4 billion of plant and acquisition investment over five years
03—Questions
Frequently Asked Questions
What drove ADM's record fiscal 1995 earnings?
Earnings were driven mainly by a 9% increase in sales volume and a 2% increase in average selling prices. Strong export demand for vegetable oils, solid domestic demand for oilseed meal, and higher corn sweetener prices all contributed. Gross profit rose $505 million to $1.6 billion, and a $43 million gain on the sale of the British Arkady business added to pre-tax income. The effective tax rate was about 33%, similar to the prior year.
How serious is the antitrust investigation for investors?
The outcome cannot yet be determined, and management has recorded no provision for liability. The grand jury probe is in an early stage, and no ADM director, officer, or employee has been charged. However, the company faces possible monetary damages, fines, penalties, and sanctions, along with multiple class actions seeking treble damages under antitrust law and securities claims. Investors should watch for further charges, settlements, or accruals in future filings, since any of these could materially affect results.
Is ADM's balance sheet financially sound?
Yes. At June 30, 1995, total assets were $9.8 billion and shareholders' equity was $5.9 billion. The company held $1.1 billion in cash and marketable securities, and its long-term debt of $2.1 billion was about 24% of total capital. Standard & Poor's rated its commercial paper at the highest level and its long-term debt AA-, while Moody's rated long-term debt Aa2. The company also had $398 million of committed bank credit lines.
Why are the sales and cost figures for 1995 so high relative to the earnings?
ADM is a high-volume, low-margin agricultural processor. Its gross sales of $15.9 billion include the total value of grain merchandised, but reported net sales of $12.7 billion include only the net margins from that grain. Gross margins are therefore thin, and profitability depends on processing volume, spreads, and effective hedging. Commodity prices can move sharply because of weather, government farm policy, and global demand, and the company hedges to limit that exposure.
What are ADM's growth plans beyond traditional commodity processing?
ADM is expanding its bioproducts business, which uses fermentation and processing to make feed-grade amino acids such as lysine, threonine, and tryptophan, along with citric acid, MSG, vitamins (riboflavin, with biotin and vitamins C and E in development), emulsifiers, and astaxanthin. It is also expanding its soy protein and specialty food ingredient lines. The company spent about $3.4 billion over the last five years on plants, expansions, and acquisitions, and it continues to fund international joint ventures such as Alfred C. Toepfer and Compagnie Industrielle et Financiere des Produits Amylaces.
04—Continue